Browse News

Found 20 articles

• Olema Oncology to Participate at Upcoming Virtual Investor Conferences

  2/23/2021

  Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that it will participate at the following upcoming virtual investor conferences: Cowen 41st Annual Health Care Conference Date and Time: March 2, 2021 at 2:10 p.m. Eastern Time

• Shasqi Announces Strategic Advisors as it Advances Click-Chemistry Based Treatments for Cancer

  2/10/2021

  Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPACTM) platform, announced today the members of its strategic advisory board, which bring a range of expertise to the company including corporate strategy, clinical development, cellular biology, and cancer therapeutics.

• Olema Oncology to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference

  12/17/2020

  Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that Sean P. Bohen, M.D., Ph.D., president and chief executive officer, will present at the 39 th Annual J.P. Morgan Virtual Healthcare Conference on Monday, January 11, 2021, at 10 a.m. Eastern Time. The presen

• Olema Oncology Announces Two Poster Presentations at the San Antonio Breast Cancer Symposium 2020

  12/7/2020

  Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced two posters relating to OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), will be presented at the San Antonio Breast Cancer Symposium (SABCS), to be held virtually from December 8-11, 2020.

• 

  Biopharma Money on the Move: November 18-24

  11/25/2020

  Find out which biopharma companies are raking in cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.

• Olema Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  11/23/2020

  Olema Pharmaceuticals, Inc. announced the closing of its previously announced initial public offering of 12,650,000 shares of its common stock, which includes 1,650,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $19.00 per share.

• 

  Olema Oncology Prices IPO at $19 Per Share, Expects Gross Proceeds of $209 Million

  11/19/2020

  In the IPO announcement, Olema Oncology notes it has granted the underwriters a 30-day option to buy up to 1,650,000 more common stock shares at the IPO price.

• Olema Oncology Announces Pricing of Initial Public Offering

  11/18/2020

  SAN FRANCISCO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced the pricing of its initial public offering of 11,000,000 shares of its common stock at a price to the public of $19.00 per share. The gross proceeds to Olema Oncology from the offering, before deducting the underwriting discount

• Olema Oncology Appoints Biopharma Industry Veteran Sandra J. Horning, M.D., to Board of Directors

  11/13/2020

   Olema Oncology, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced the appoint

• Olema Oncology Announces Clinical Trial to Evaluate OP-1250 in Combination with Palbociclib (IBRANCE®) in Advanced Metastatic Breast Cancer

  11/13/2020

  Olema Oncology, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced a clinical trial to evaluate OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in combination with palbocic

• Olema Oncology Announces Clinical Collaboration to Evaluate OP-1250 in Combination with Advanced Breast Cancer Therapies

  10/26/2020

  Olema Oncology, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced a clinical collaboration agreement with Novartis to evaluate OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in combination with each of Kisqali®

• Olema Oncology to Present Preclinical Data on OP-1250, Lead Program in Breast Cancer, at ENA 2020

  10/20/2020

  Olema Oncology, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced it will present preclinical data on the mechanism of action of OP-1250 in a poster session at the 32 nd EORTC-NCI-AACR (ENA) Symposium, which will be h

• Olema Oncology Raises $85 Million in Series C Financing to Advance Clinical Development of OP-1250 in Breast Cancer

  10/1/2020

  - Financing in Support of Company's Goal of Developing Targeted Therapies to Improve the Lives of Women with Cancer - Lead Investor Vivo Capital is Joined by Additional New Investors Avoro Capital Advisors, Funds and Accounts Managed by BlackRock, Deerfield Management Company and OrbiMed, and All Existing Institutional Investors

• 

  BioSpace Movers & Shakers, Sept. 25

  9/25/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers and Shakers.

• Olema Oncology Names Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer

  9/17/2020

  Olema Oncology, a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for women's cancers, today announced the appointment of

• 

  BioSpace Movers & Shakers, Sept. 11

  9/11/2020

  Biopharma and life sciences companies bolster their leadership teams and boards with these Movers & Shakers.

• Olema Oncology Announces Appointment of Ian T. Clark and Cynthia M. Butitta to Board of Directors

  9/10/2020

  Former Genentech CEO and Former Kite COO/CFO Bring Extensive Oncology Drug Development and Commercialization Experience to Company

• Olema Oncology Appoints Biotechnology Industry Veterans to Round Out Executive Team

  9/10/2020

  Olema Oncology, a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for women's cancers, today announced it has strengthened its executive team with the appointment of Shane Kovacs , M.B.A., as Chief Operating Officer/Chief Financial Officer, Kinney Horn as Chief Business O

• 

  With $54 Million in Financing, Olema Oncology Takes Aim at Breast Cancer

  7/22/2020

  San Francisco-based Olema Oncology secured $54 million in an oversubscribed Series B financing round to support the development of its lead breast cancer treatment, as well as expand its ongoing research and development programs.

• Olema Oncology Announces $54 Million Series B Financing

  7/22/2020

  Olema Oncology, a biopharmaceutical company developing innovative targeted therapies for women's cancers, today announced the closing of an oversubscribed $54 million Series B financing.